A Study of CTD402 in T-ALL/LBL Patients
A phase 1/2 trial of CTD402 CAR T Cell Injection in acute lymphoblastic leukaemia and non-Hodgkin lymphoma, run by Imviva Bio, now recruiting.
Overview
A Study of CTD402 in T-ALL/LBL Patients is a phase 1/2 interventional study registered as NCT07070219 by Imviva Bio, with 118 participants planned, started 2025-10-07 and due to reach its primary completion in 2028-09-30. Interventions recorded: CTD402 CAR T Cell Injection.
Similar pages
not linked directly; found by shared links- TrialPhase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialClinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialMB-105 in Patients With CD5 Positive T-cell Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialGT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.